Literature DB >> 21907470

Treatment of bisphosphonate-related osteonecrosis of the jaws: presentation of a protocol and an observational longitudinal study of an Italian series of cases.

Sebastiano Ferlito1, Sergio Puzzo, Filippo Palermo, Placido Verzì.   

Abstract

The aim of this study was to evaluate the efficacy of a treatment protocol for bisphosphonate-related osteonecrosis of the jaws (BRONJs). We conducted a longitudinal observational non-controlled study in 94 patients with confirmed BRONJ. Treatment was in two phases: supportive (antimicrobial mouth rinses, antibiotics, and anti-inflammatory steroids) to minimise infection and pain before the formation of a bony sequestrum; and surgical plus pharmacological treatment (sequestrectomy with antibiotic prophylaxis) after the sequestrum had developed. We did a Kaplan-Meier analysis (survival curve) to evaluate the time from the initial assessment until the formation of the bony sequestrum (endpoint), and a log-rank (Mantel-Haenszel) test to compare the formation times of the sequestra in men and women. Ninety-one of the 94 patients developed sequestra and were operated on. Three patients were withdrawn from the study because of severe pain and were treated by debridement before the sequestra developed. The results showed that sequestra developed within 15 months in all 91 patients. The Kaplan-Meier analysis showed that the mean time to formation of a sequestrum was 8 months (range 5-11). The difference between the mean time for men (5 months, range 2-8) and women (9 months, range 6-12) was highly significant (p<0.0001). Within the limits of this study, we conclude that by waiting for the formation of bony sequestra while controlling infection and pain, it is possible to do a conservative resection, unless pain is severe or there is a risk of fracture. This non-aggressive approach permits the removal of all necrotic bone, avoids damage to adjacent healthy bone, and does not result in recurrences.
Copyright © 2011 The British Association of Oral and Maxillofacial Surgeons. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21907470     DOI: 10.1016/j.bjoms.2011.08.004

Source DB:  PubMed          Journal:  Br J Oral Maxillofac Surg        ISSN: 0266-4356            Impact factor:   1.651


  17 in total

1.  Effect of the cumulative dose of zoledronic acid on the pathogenesis of osteonecrosis of the jaws.

Authors:  Meral Günaldi; Cigdem Usul Afsar; Berna Bozkurt Duman; Ismail Oguz Kara; Ufuk Tatli; Berksoy Sahin
Journal:  Oncol Lett       Date:  2015-04-27       Impact factor: 2.967

Review 2.  A literature review of perioperative antibiotic administration in surgery for medication-related osteonecrosis of the jaw.

Authors:  Masaya Akashi; Junya Kusumoto; Daisuke Takeda; Takashi Shigeta; Takumi Hasegawa; Takahide Komori
Journal:  Oral Maxillofac Surg       Date:  2018-10-16

3.  Wound healing protein profiles in the postoperative exudate of bisphosphonate-related osteonecrosis of mandible.

Authors:  Soung Min Kim; Mi Young Eo; Yun Ju Cho; Yeon Sook Kim; Suk Keun Lee
Journal:  Eur Arch Otorhinolaryngol       Date:  2017-06-24       Impact factor: 2.503

Review 4.  Surgical management of bisphosphonate-related osteonecrosis of the jaws: literature review.

Authors:  Larissa Fernandes Silva; Cláudia Curra; Marcelo Salles Munerato; Carlos Cesar Deantoni; Mariza Akemi Matsumoto; Camila Lopes Cardoso; Marcos Martins Curi
Journal:  Oral Maxillofac Surg       Date:  2015-12-11

5.  Stage-specific therapeutic strategies of medication-related osteonecrosis of the jaws: a systematic review and meta-analysis of the drug suspension protocol.

Authors:  Luca Ramaglia; Agostino Guida; Vincenzo Iorio-Siciliano; Alessandro Cuozzo; Andrea Blasi; Anton Sculean
Journal:  Clin Oral Investig       Date:  2018-01-13       Impact factor: 3.573

6.  Learning from experience. Proposal of a refined definition and staging system for bisphosphonate-related osteonecrosis of the jaw (BRONJ).

Authors:  A Bedogni; V Fusco; A Agrillo; G Campisi
Journal:  Oral Dis       Date:  2012-02-22       Impact factor: 3.511

Review 7.  Osteonecrosis of the Jaw and Antiresorptive Agents in Benign and Malignant Diseases: A Critical Review Organized by the ECTS.

Authors:  Athanasios D Anastasilakis; Jessica Pepe; Nicola Napoli; Andrea Palermo; Christos Magopoulos; Aliya A Khan; M Carola Zillikens; Jean-Jacques Body
Journal:  J Clin Endocrinol Metab       Date:  2022-04-19       Impact factor: 6.134

Review 8.  Medication Related Osteonecrosis of the Jaw: 2015 Position Statement of the Korean Society for Bone and Mineral Research and the Korean Association of Oral and Maxillofacial Surgeons.

Authors:  Kyoung Min Kim; Yumie Rhee; Yong-Dae Kwon; Tae-Geon Kwon; Jeong Keun Lee; Deog-Yoon Kim
Journal:  J Bone Metab       Date:  2015-11-30

9.  RANK/RANKL/OPG signaling pathways in necrotic jaw bone from bisphosphonate-treated subjects.

Authors:  C Di Nisio; V L Zizzari; S Zara; M Falconi; G Teti; G Tetè; A Nori; V Zavaglia; A Cataldi
Journal:  Eur J Histochem       Date:  2015-02-03       Impact factor: 3.188

Review 10.  Surgical treatment vs. conservative treatment in intravenous bisphosphonate-related osteonecrosis of the jaws. Systematic review.

Authors:  Aida Comas-Calonge; Rui Figueiredo; Cosme Gay-Escoda
Journal:  J Clin Exp Dent       Date:  2017-02-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.